First Line Therapy for Metastatic Pancreatic Cancer

  • Jamie Jarboe Tufts Cancer Center. Boston, MA, USA
  • Muhammad Wasif Saif Tufts Cancer Center. Boston, MA, USA
DOI: https://doi.org/10.6092/1590-8577/1667
Keywords: 130-nm albumin-bound paclitaxel, CA-19-9 Antigen, oxaliplatin, Pancreatic Neoplasms

Abstract

Metastatic pancreatic cancer remains a difficult disease to treat; however, there are more new drug combinations on the horizon each week. We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data.

Image: MPACT control and experimental arms.

Downloads

Download data is not yet available.

References

Cancer Facts and Figures 2013. American Cancer Society

Burris HA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-13, 1997.

Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-25, 2011.

Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31, 2013(Suppl): Abstract #4005.

Komar G, et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-7.

5. Von Hoff D, et al. Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. JCO 2011;29:4548-4554.

Frese K, et al. nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery 2012; 261-269.

Chiorean EG, Von Hoff DD, Ervin TJ, Arena FP, Infante JR, Bathini VG, et al. CA 19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4058.

Moore MJ, Von Hoff DD, Ervin TJArena FP, Chiorean EG, Infante JR, et al. Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 31, 2013(Suppl): Abstract #4059.

MPACT control and experimental arms
Published
2013-07-10
How to Cite
JarboeJ., & SaifM. (2013). First Line Therapy for Metastatic Pancreatic Cancer. JOP. Journal of the Pancreas, 14(4), 340-343. https://doi.org/10.6092/1590-8577/1667
Issue
Vol 14 No 4 (2013): July - p. 304-474
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Copyright (c) 2014 Jamie Jarboe, Muhammad Wasif Saif

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.